Characteristics and Treatment Trends of Young Breast Cancer in China

October 12, 2021 updated by: PENG YUAN, Cancer Institute and Hospital, Chinese Academy of Medical Sciences

An Study on the Trend of Change and Influencing Factors of Clinicopathologic Characteristics, Diagnosis and Treatment Pattern, and Survival Status of Young Breast Cancer in China

To describe the clinical characteristics, the diagnosis and treatment, the survival status and change trend of young breast cancer patients in China from 2000 to 2015, and to explore and discuss the main influencing factors.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

In this study, medical records and follow-up information of young breast cancer patients (age ≤35 years at first diagnosis) who were first diagnosed and treated in the years (2000, 2003, 2006, 2009, 2012 and 2015) were collected from multiple hospitals in China from 2000 to 2015, to establish a retrospective cohort of young breast cancer patients. Clinical characteristics, diagnosis and treatment, and survival rates of young breast cancer patients from 2000 to 2015 were analyzed. To explore the main factors affecting the clinical diagnosis and treatment and the survival of patients.

Study Type

Observational

Enrollment (Anticipated)

1000

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 35 years (Adult)

Accepts Healthy Volunteers

N/A

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Young Breast cancer patients (≤35 years old) in China

Description

Inclusion Criteria:

  • Young Breast cancer patients (≤35 years old) in China

Exclusion Criteria:

  • Breast cancer patients (>35 years old) in China

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
1
Young breast cancer patients in China from 2000 to 2015, of whom the clinical features, diagnosis and treatment models and survival status are described.
Procedure: Clinical characteristics, diagnosis and treatment, survival status
Describe the clinical characteristics, diagnosis and treatment, survival status and the trends of young breast cancer
Other Names:
  • This is a retrospective study to observe and describe the diagnosis and treatment of previous young breast cancer patients without intervention

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Clinical features and trend
Time Frame: Between 2000 and 2015
To describe the clinical characteristics and trends of young breast cancer patients in China
Between 2000 and 2015
Diagnosis and treatment and trend
Time Frame: Between 2000 and 2015
To describe the methods of diagnosis and treatment in young breast cancer patients in China and the changing trend, to explore the main factors affecting diagnosis and treatment
Between 2000 and 2015
Survival situation and change trend
Time Frame: Between 2000 and 2015
To describe the survival and change trend of young breast cancer patients in China, to explore the main factors affecting the prognosis of young breast cancer patients
Between 2000 and 2015

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Anticipated)

November 1, 2021

Primary Completion (Anticipated)

October 1, 2023

Study Completion (Anticipated)

October 1, 2024

Study Registration Dates

First Submitted

August 15, 2021

First Submitted That Met QC Criteria

September 23, 2021

First Posted (Actual)

October 5, 2021

Study Record Updates

Last Update Posted (Actual)

October 13, 2021

Last Update Submitted That Met QC Criteria

October 12, 2021

Last Verified

October 1, 2021

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • NCC2985

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Breast Cancer

Clinical Trials on Clinical characteristics, diagnosis and treatment, survival status

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Benin

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe